| Desipramine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Desipramine | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | |
| Desipramine | hsa00190 | Oxidative phosphorylation | 5.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
| Desipramine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
| Desipramine | hsa00620 | Pyruvate metabolism | 3.90E-02 | 2 | P07195, P11766 | LDHB, ADH5 | More | |
| Desipramine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Desipramine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | |
| Desipramine | hsa00830 | Retinol metabolism | 3.15E-02 | 1 | P00325 | ADH1B | More | |
| Desipramine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.00E-02 | 1 | P09211 | GSTP1 | More | |
| Desipramine | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
| Desipramine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Desipramine | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.43E-02 | 1 | P50213 | IDH3A | More | |
| Desipramine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Desipramine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
| Desipramine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Desipramine | hsa02010 | ABC transporters | 1.98E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
| Desipramine | hsa03010 | Ribosome | 1.08E-04 | 11 | P62753, P25398, P32969, P40429, P62829, Q07020, P18077, P36578, P27635, P05386, P62249 | RPS6, RPS12, RPL9, RPL13A, RPL23, RPL18, RPL35A, RPL4, RPL10, RPLP1, RPS16 | More | |
| Desipramine | hsa03020 | RNA polymerase | 1.15E-03 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | |
| Desipramine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Desipramine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | |
| Desipramine | hsa03060 | Protein export | 4.46E-03 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | |
| Desipramine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
| Desipramine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
| Desipramine | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04071 | Sphingolipid signaling pathway | 1.17E-03 | 6 | P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | |
| Desipramine | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | |
| Desipramine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Desipramine | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
| Desipramine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Desipramine | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04141 | Protein processing in endoplasmic reticulum | 3.07E-03 | 7 | P18848, P07384, O95487, O60337, P11142, P07900, O95816 | ATF4, CAPN1, SEC24B, MARH6, HSPA8, HSP90AA1, BAG2 | More | |
| Desipramine | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
| Desipramine | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04213 | Longevity regulating pathway - multiple species | 2.83E-03 | 3 | P08069, Q9Y4H2, Q13547 | IGF1R, IRS2, HDAC1 | More | |
| Desipramine | hsa04217 | Necroptosis | 6.67E-07 | 18 | P01375, P01568, P48023, Q13489, P42224, Q14765, P07900, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q99878, Q93077, Q13557, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AA1, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, HIST1H2AC, CAMK2D, CHMP2A, PPID | More | |
| Desipramine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
| Desipramine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Desipramine | hsa04360 | Axon guidance | 1.50E-02 | 3 | P20827, P23528, Q06124 | EFNA1, CFL1, PTPN11 | More | |
| Desipramine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04530 | Tight junction | 2.08E-02 | 3 | P63261, Q9Y478, Q92974 | ACTG1, PRKAB1, ARHGEF2 | More | |
| Desipramine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04610 | Complement and coagulation cascades | 5.18E-06 | 1 | P0C0L4 | C4A | More | |
| Desipramine | hsa04612 | Antigen processing and presentation | 4.24E-05 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | |
| Desipramine | hsa04613 | Neutrophil extracellular trap formation | 3.76E-04 | 10 | P11215, Q13547, P04908, Q93077, P58876, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Desipramine | hsa04621 | NOD-like receptor signaling pathway | 2.27E-02 | 9 | Q9H1Y0, P43490, O00463, Q05823, P01375, P49913, P59665, P59666, P12838 | ATG5, PBEF1, TRAF5, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Desipramine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
| Desipramine | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
| Desipramine | hsa04650 | Natural killer cell mediated cytotoxicity | 4.40E-05 | 9 | P01375, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | |
| Desipramine | hsa04657 | IL-17 signaling pathway | 2.51E-03 | 6 | P07900, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, CXCL2, MMP9, LCN2, TNF, IL1B | More | |
| Desipramine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Desipramine | hsa04714 | Thermogenesis | 1.73E-04 | 7 | Q16539, P15336, P63261, P33121, Q9Y478, Q16718, O14521 | MAPK14, ATF2, ACTG1, ACSL1, PRKAB1, NDUFA5, SDHD | More | |
| Desipramine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
| Desipramine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Desipramine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
| Desipramine | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Desipramine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Desipramine | hsa04913 | Ovarian steroidogenesis | 7.72E-03 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | |
| Desipramine | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
| Desipramine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
| Desipramine | hsa04920 | Adipocytokine signaling pathway | 2.80E-02 | 2 | Q06124, Q9Y478 | PTPN11, PRKAB1 | More | |
| Desipramine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Desipramine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Desipramine | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
| Desipramine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
| Desipramine | hsa04932 | Non-alcoholic fatty liver disease | 6.73E-05 | 9 | P01375, P49841, P18848, P48023, P01584, P13073, O15239, Q16718, O14521 | TNF, GSK3B, ATF4, FASLG, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | |
| Desipramine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Desipramine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | |
| Desipramine | hsa04966 | Collecting duct acid secretion | 1.29E-03 | 2 | P02730, P00918 | SLC4A1, CA2 | More | |
| Desipramine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Desipramine | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
| Desipramine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Desipramine | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Desipramine | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
| Desipramine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
| Desipramine | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | |
| Desipramine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | |
| Desipramine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Desipramine | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Desipramine | hsa05130 | Pathogenic Escherichia coli infection | 9.80E-03 | 4 | Q92974, P63261, Q06124, O95487 | ARHGEF2, ACTG1, PTPN11, SEC24B | More | |
| Desipramine | hsa05133 | Pertussis | 3.60E-03 | 1 | P0C0L4 | C4A | More | |
| Desipramine | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
| Desipramine | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | |
| Desipramine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Desipramine | hsa05144 | Malaria | 1.72E-03 | 4 | P60033, P01375, P35443, P26718 | CD81, TNF, THBS4, KLRK1 | More | |
| Desipramine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Desipramine | hsa05150 | Staphylococcus aureus infection | 1.48E-04 | 9 | P0C0L4, P21730, P21462, O75015, P13646, P59665, P59666, P12838, P49913 | C4A, C5AR1, FPR1, FCGR3B, KRT13, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | |
| Desipramine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Desipramine | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Desipramine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | |
| Desipramine | hsa05171 | Coronavirus disease - COVID-19 | 6.98E-05 | 12 | P01584, P62753, P25398, P62249, P40429, P36578, P32969, P27635, Q07020, P18077, P05386, P62829 | IL1B, RPS6, RPS12, RPS16, RPL13A, RPL4, RPL9, RPL10, RPL18, RPL35A, RPLP1, RPL23 | More | |
| Desipramine | hsa05202 | Transcriptional misregulation in cancer | 1.33E-04 | 16 | Q15532, Q13315, P14780, P27930, Q15744, Q16548, P11215, O15550, P08069, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | SS18, ATM, MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, UTX, IGF1R, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | |
| Desipramine | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Desipramine | hsa05204 | Chemical carcinogenesis | 4.00E-02 | 1 | P09211 | GSTP1 | More | |
| Desipramine | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | |
| Desipramine | hsa05211 | Renal cell carcinoma | 1.06E-02 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
| Desipramine | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
| Desipramine | hsa05218 | Melanoma | 9.63E-04 | 4 | P08069, P09619, Q9GZP0, Q02750 | IGF1R, PDGFRB, PDGFD, MAP2K1 | More | |
| Desipramine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
| Desipramine | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | |
| Desipramine | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | |
| Desipramine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
| Desipramine | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
| Desipramine | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Desipramine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Desipramine | hsa05332 | Graft-versus-host disease | 1.91E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
| Desipramine | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
| Desipramine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.71E-03 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | |
| Desipramine | hsa05414 | Dilated cardiomyopathy | 2.58E-03 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
| Desipramine | hsa05415 | Diabetic cardiomyopathy | 5.78E-05 | 12 | P17252, P05141, P14598, Q15080, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557, P04406 | PRKCA, SLC25A5, NCF1, NCF4, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D, GAPDH | More | |
